Chronic Kidney Disease research hub
32 indexed studies · 14 currently recruiting
- authorisedTherapeutic exploratory (Phase II)
Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)
This study is looking at a new treatment called Survodutide for people with Chronic Kidney Disease (CKD). It aims to see if this treatment can help reduce a protein called albumin in the urine, which is a sign of kidney damage.
Germany · Spain · Netherlands - recruitingNA
Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care
This study checks if pharmacists using special guides can help people with type 2 diabetes and early kidney damage get the right medicines. It compares this to standard care for those without a regular doctor, aiming to improve long-term health.
Canada - active not recruitingPHASE2
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
This study looks at a new medicine, vicadrostat, combined with empagliflozin, for adults with chronic kidney disease. Participants will take pills daily for 3 months, with regular checks on their kidney health and general well-being. It aims to see if starting medicines at different times impacts results.
United States · Argentina · Australia - recruitingPHASE3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This study looks at a new medicine called orforglipron for people with heart disease or kidney disease. We want to see if it can improve their heart health over about five years. Half the people will get the new medicine, and half will get a dummy medicine (placebo).
Argentina · Australia · Austria - recruitingPHASE3
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
This study is for children aged 6 months to 17 years with long-term kidney disease (CKD) and too much protein in their urine. It tests a new medicine called finerenone to see if it can improve kidney health alongside existing treatments. Researchers want to check how safe and effective it is.
United States · Argentina · Australia - not yet recruitingNA
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
This study in France looks at how blood vessels work in people with or at risk of kidney disease. It uses two new non-invasive devices, HEMI and SPG-NINOX, to check tiny blood vessels. The goal is to understand changes linked to heart, metabolism, and kidney problems.
France - active not recruiting
What Are the Determinations of Adult Progressive CKD? The Renal Impairment In Secondary Care (RIISC) Study
This study, called RIISC, wants to understand why some people with chronic kidney disease (CKD) get worse over time. By looking closely at people at higher risk, researchers hope to find better ways to predict and treat CKD, improving care for everyone.
United Kingdom - recruitingPHASE3
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
This study for children aged 2-17 with kidney disease looks at a medicine called empagliflozin. We want to see if it helps their kidneys and how well their body handles it. Participants take the medicine or a dummy pill for 6 months, then everyone takes the medicine for a year.
United States · Argentina · Australia - recruitingPHASE3
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
This study looks at a new medicine called roxadustat for children and teenagers with kidney disease and low red blood cells (anemia). It's a pill, hoping to be a new way to treat this condition instead of injections.
Belgium · Bulgaria · Croatia - recruiting
Optical Coherence Tomography And NEphropathy: The OCTANE Study
This study looks at changes in eye blood vessels in people with high blood pressure and kidney disease, compared to healthy individuals. It uses a simple eye scan (OCT) to see if these changes happen and if treatments help improve them.
United Kingdom - recruiting
Kidney Sodium Functional Imaging
This study uses a special MRI scan to measure salt in your kidneys. It aims to understand how kidney diseases like chronic kidney disease and kidney stones affect your kidneys' ability to manage water, which is important for staying healthy, especially in warm weather.
Canada - recruitingNA
Feasibility and Pilot Testing of "My Heart and CKD" Online Shared Decision Aid
This study is testing a new online tool called 'My Heart and CKD'. It helps people with kidney and heart disease, and their doctors, make important decisions about heart treatments. It aims to make sure choices match what's best for each person.
Canada - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A clinical study to investigate the safety, tolerability and pharmacokinetic profile of single ascending concentrations of OPT101 in peritoneal dialysis patients.
This study is looking at a new medicine called OPT101 for people with long-term kidney disease who are on dialysis. It will check if the medicine is safe, how the body handles it, and if different doses cause any problems.
Latvia - not yet recruitingPHASE3
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
This study looks at a new medicine called elecoglipron for people with long-term kidney disease. We want to see if it helps improve health compared to a dummy pill (placebo). Participants will also be taking existing kidney disease treatments like dapagliflozin. It's a large study, involving many people to get clear results.
United States · Argentina · Australia - active not recruitingPHASE2
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
This study is looking into a new medicine called tirzepatide. It aims to see if tirzepatide can help people with kidney disease who are also overweight or living with obesity, whether or not they have type 2 diabetes.
United States · Austria · Canada - recruiting
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
This study looks at how a new medicine, finerenone, is used by people in everyday life. It's for people with long-term kidney problems and type 2 diabetes. Researchers will check if it's safe and how well it works using existing health records, not new tests.
United States · Germany · Japan - recruiting
Kidney Check: Diabetes, Blood Pressure & Kidney Health Checks & Care in Indigenous Communities.
This study offers free kidney health checks for Indigenous people aged 10-80 in rural areas of Canada. It aims to find kidney problems early, and those at risk of diabetes and high blood pressure, to improve care and create a lasting health system for these communities.
Canada - recruitingPHASE3
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
This study looks at how safe a new medicine called finerenone is for children and young people (aged 1-18) with long-term kidney disease, when taken with other common kidney medicines. It also checks if it helps reduce protein in their urine.
United States · Argentina · Australia - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study in healthy men to learn about how the body absorbs, processes, and removes radioactively labeled BAY 3283142
This study is looking at how a new drug, BAY 3283142, moves through the bodies of healthy men. It will help scientists understand how the body uses and gets rid of this medicine to treat chronic kidney disease.
Netherlands - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to learn about the safety of BAY 3283142 in people with mild to moderate high blood pressure
This study is looking at a new medicine called BAY 3283142. It’s for adults who have slightly high blood pressure and ongoing kidney problems. We want to see how safe the medicine is and if it causes any side effects at different doses.
Germany - active not recruitingPHASE3
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
This study looks at a new medicine called ravulizumab for people with kidney disease having heart surgery. It aims to see if the medicine can prevent serious kidney problems after the operation. It's for adults aged 18-90.
United States · Argentina · Australia - authorisedPhase I and Phase II (Integrated)- Other
A 6-Month, Randomized, Double-Blind Study to Evaluate the Effect of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD)
This study looks at how a medicine called dapagliflozin affects the heart in people with long-term kidney disease. Researchers want to see if it changes the heart's size and how well it pumps after six months. Half the people will get the medicine, and half will get a dummy pill.
Denmark - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to learn more about how safe nurandociguat is and how it affects the way the body processes rosuvastatin and dabigatran in healthy adults
This study is looking at a new medicine called nurandociguat in healthy adults. It wants to find out if it's safe and how it interacts with two other common medicines, rosuvastatin (for cholesterol) and dabigatran (a blood thinner), to understand its effects better.
Germany - authorisedTherapeutic use (Phase IV)
CANIDIAP; CANagliflozin In DIAlysis Patients
This study is looking at how a kidney medicine called canagliflozin (known as Invokana) works in people on dialysis. We want to see how much of the medicine reaches certain parts of the body, which helps us understand if it's working as intended.
Netherlands - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazanavir and to assess the proportion of BAY3283142 that reaches the blood when taken by mouth.
This study is looking at a new medicine called BAY3283142. We want to understand how it travels through the body when healthy people take it with another medicine called atazanavir. The main goal is to see how much of BAY3283142 gets into the blood after someone swallows it.
Netherlands - authorisedHuman Pharmacology (Phase I)- First administration to humans
A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease
This study is testing a new medicine, OJR520, for people with kidney disease and healthy volunteers. The main goals are to check if it's safe, how the body handles it, and if it has any effects. It’s a carefully designed study where some people get the medicine and others get a dummy treatment.
Germany · Romania - recruiting
INCLUDE-CKD: INCLUsive Digital carE for Chronic Kidney Disease
This study looks at how a digital tool, MyRenalCare, helps people with kidney disease. Researchers want to understand who uses it, how often, and if it improves health, saves money, and is good for the environment.
United Kingdom - authorisedHuman Pharmacology (Phase I)- Other
A study to learn about how a new nurandociguat tablet is absorbed and processed in the body compared to an old tablet and how food affects the way the new tablet is absorbed and processed in the body
This study is looking at a new tablet, called nurandociguat, for people with long-term kidney problems. We want to understand how the body takes in and uses this new tablet, especially when compared to an older version and how food might change this process.
Germany - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Dapagliflozin 10 mg film-coated tablets (Polfa Tarchomin S.A., Poland) versus Froxiga 10 mg film-coated tablets (AstraZeneca AB, Sweden) in healthy volunteers under fasting conditions.
This study is testing if a new version of the diabetes and heart failure medicine, Dapagliflozin, works the same as the existing one. Healthy adults take both medicines to see if they're absorbed in the body in the same way.
Czechia - recruiting
Improving chronic kidney disease identification and assessing its association with health inequalities in coding practices
This study aims to improve how a long-term kidney condition (CKD) is found and recorded in GP notes. It uses a new computer tool to make sure nearly everyone with CKD gets the right care and no one is wrongly coded.
United Kingdom · England - ongoing, recruitingTherapeutic exploratory (Phase II)
(22040 ALPINE 1) A Phase 2b dose-finding, randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of BAY 3283142 on top of standard of care in reducing albuminuria in patients with chronic kidney disease
This study is testing a new medicine, BAY 3283142, for people with long-term kidney disease. We want to see if it helps reduce kidney damage by lowering a protein called albumin in your urine, compared to a dummy pill. It's a key step to finding better treatments.
Belgium · Sweden · Spain - active not recruitingPHASE3
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
This study investigates if a new drug, ziltivekimab, can lower the risk of heart attacks and strokes in people with heart disease, kidney disease, and ongoing inflammation. Participants will receive either the drug or a dummy treatment to see if it makes a difference.
United States · Argentina · Australia